Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Recombinant Protein Market Size, Share, Trends, and Forecast 2026-2035 - Global Growth Outlook | Biologics Demand Fuels 11.21% CAGR and a USD 6.11 Billion Opportunity

globenewswire.com
MRK Merck KGaA is mentioned as a prominent participant in the recombinant protein market, indicating its involvement in this growing sector. The article does not provide specific sentiment towards the company's performance or prospects. BIO Bio-Rad Laboratories, Inc. is listed as a prominent participant in the recombinant protein market. The article does not offer specific sentiment regarding the company's performance or future outlook. ABT Abbott is mentioned as a prominent participant in the recombinant protein market. The article does not provide specific sentiment or details about the company's performance within this market.

Recombinant Protein Market Size, Share, Trends, and Forecast 2026-2035 - Global Growth Outlook | Biologics Demand Fuels 11.21% CAGR and a USD 6.11 Billion Opportunity Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Recombinant Protein Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)" has been added to ResearchAndMarkets.com's offering.

Recombinant Protein Market Size and Forecast

The global recombinant protein market was valued at USD 2.11 Billion in 2025 and is projected to reach USD 6.11 Billion by 2035. The market is expected to expand at a CAGR of 11.21% during the 2026-2035 forecast period, supported by growing demand for biologics, the rising prevalence of chronic diseases, advances in protein expression technologies, and broader therapeutic and research applications.

Recombinant Protein Market Overview

Recombinant protein market growth is being strengthened by increased investment in biologics, targeted therapies, diagnostic development, and life sciences research. Pharmaceutical and biotechnology companies are adopting advanced expression platforms, including CHO cell, E. coli expression, baculovirus, and yeast expression systems, to improve production efficiency, scalability, quality, and consistency.

Applications continue to expand across therapeutic protein development, enzyme production, antibodies, cytokines, growth factors, immune checkpoint proteins, and regulatory proteins. Demand is also rising as research organizations pursue more precise approaches to oncology, immunology, infectious diseases, regenerative medicine, and chronic disease management.

Market Growth Drivers and Emerging Trends

The rising global burden of chronic and complex diseases is increasing the need for effective biologic treatments. Recombinant proteins are central to many drug discovery and development programs, particularly those focused on targeted treatment pathways. Expanding clinical pipelines and the increasing adoption of protein-based therapies are expected to create further opportunities for manufacturers, research institutions, and technology providers.

Regulatory modernization is also influencing market expansion. In October 2025, the U.S. Food and Drug Administration introduced measures intended to streamline biosimilar development by allowing greater reliance on analytical similarity data and reducing certain clinical trial requirements. These changes may lower development barriers, accelerate market entry, and improve access to cost-effective biologic therapies in areas such as oncology and autoimmune disease.

Other significant recombinant protein market trends include continued innovation in expression systems, growing monoclonal antibody production, increased investment in scalable biologics manufacturing, and stronger collaboration among pharmaceutical companies, biotechnology firms, and research organizations.

Market Segmentation

The recombinant protein market is segmented by product type, application, and region.

By Product Type:

By Application:

By Region:

Application and Regional Market Analysis

The therapeutics segment accounted for more than 34.2% of the global market during the historical period. Its leadership reflects strong demand for biologics, targeted treatments, and protein-based medicines. Continued expansion of drug development pipelines and clinical applications is expected to support this segment throughout the forecast period.

North America held more than 41.1% of the market during the historical period. The region benefits from established biopharmaceutical infrastructure, advanced R&D capabilities, significant healthcare investment, and high adoption of biologic therapies. The use of sophisticated expression technologies for large-scale protein manufacturing further supports North America's position as a major center for recombinant protein innovation and commercialization.

Leading Recombinant Protein Market Companies

Competitive analysis of the market includes patents, clinical trials, funding, investment activity, partnerships, collaborations, mergers, acquisitions, and product development strategies.

Other prominent participants include Merck KGaA, Bio-Rad Laboratories, Inc., GeneTex, Inc, Lonza Group SA, PerkinElmer Inc., Sino Biological Inc., TAKARA HOLDINGS INC., Tosoh Corporation, XENOTECH AI Pvt Ltd., NEW ENGLAND BIOLABS, INC., and Abbott.

Report Scope

The recombinant protein market report evaluates market size, growth forecasts, product and application performance, regional opportunities, competitive positioning, regulatory developments, unmet needs, and commercialization challenges. It also examines how strategic partnerships, funding, clinical research, mergers, and acquisitions are shaping the global competitive landscape through 2035.

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/y0yh9a

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.